These treatments could be an option for LM and specific uterine sarcoma subtypes, as enhanced collagen deposition and YAP activity are associated with undifferentiated uterine sarcoma and endometrial stromal sarcoma aggressiveness [21, 22]. Here, YAP1 is linked to endometrioid stromal sarcoma.